Development and Validation of Nomograms for Predicting Pneumonia in Patients with COVID-19 and Lung Cancer
DOI: https://doi.org/10.2147/jir.s456206
IF: 4.5
2024-06-08
Journal of Inflammation Research
Abstract:Yiyue Xu, 1, &ast Haoqian Li, 1, &ast Xiaoqing Wang, 2 Butuo Li, 1 Aiqin Gao, 1 Qian Zhao, 1 Linlin Yang, 1 Wenru Qin, 1 Linlin Wang 1 1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China; 2 Department of Portal Hypertension, Shandong Public Health Clinical Center, Shandong University, Jinan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Linlin Wang, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 JiYan Road, Jinan, 250117, People's Republic of China, Tel +86-13793187739, Email Background: COVID-19 has spread worldwide, becoming a global threat to public health and can lead to complications, especially pneumonia, which can be life-threatening. However, in lung cancer patients, the prediction of pneumonia and severe pneumonia has not been studied. We aimed to develop effective models to assess pneumonia after SARS-CoV-2 infection in lung cancer patients to guide COVID-19 management. Methods: We retrospectively recruited 621 lung cancer patients diagnosed with COVID-19 via SARS-CoV-2 RT-PCR analysis in two medical centers and divided into training and validation group, respectively. Univariate and multivariate logistic regression analysis were used to identify independent risk factors of all-grade pneumonia and ≥ grade 2 pneumonia in the training group. Nomograms were established based on independent predictors and verified in the validation group. C-index, ROC curves, calibration curve, and DCA were used to evaluate the nomograms. Subgroup analyses in immunotherapy or thoracic radiotherapy patients were then conducted. Results: Among 621 lung cancer patients infected with SARS-CoV-2, 203 (32.7%) developed pneumonia, and 66 (10.6%) were ≥ grade 2. Multivariate logistic regression analysis showed that diabetes, thoracic radiotherapy, low platelet and low albumin at diagnosis of COVID-19 were significantly associated with all-grade pneumonia. The C-indices of the prediction nomograms in the training group and validation group were 0.702 and 0.673, respectively. Independent predictors of ≥ grade 2 pneumonia were age, KPS, thoracic radiotherapy, platelet and albumin at COVID 19 diagnosis, with C-indices of 0.811 and 0.799 in the training and validation groups. In the thoracic radiotherapy subgroup, 40.8% and 11% patients developed all-grade and ≥grade 2 pneumonia, respectively. The rates in the immunotherapy subgroup were 31.3% and 6.6%, respectively. Conclusion: We developed nomograms predicting the probability of pneumonia in lung cancer patients infected with SARS-CoV-2. The models showed good performance and can be used in the clinical management of COVID-19 in lung cancer patients. Higher-risk patients should be managed with enhanced protective measures and appropriate intervention. Keywords: COVID-19, pneumonia, lung cancer, risk factor, nomogram In December 2019, the novel Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) spread rapidly throughout the world, 1 causing a global public health problem. 2 As the pandemic progressed and vaccination advanced, herd immunity enhanced and the proportion of severe cases and mortality gradually decreased over time, and the majority of infected individuals had relatively mild disease without signs of pneumonia. However, patients with underlying disease are still at elevated risk of complications, especially pneumonia. 3 According to the updated global cancer report, lung cancer is ranked the second place in terms of incidence and first in cancer-related mortality rate. 4 Based on the characteristics of pulmonary neoplasms and treatment-related toxicity, it is therefore highly important to focus on advancing the management of COVID-19 pneumonia in lung cancer patients, especially those who received immunotherapy or thoracic radiotherapy (TRT). Immunotherapy represented by immune checkpoint inhibitors (ICIs) impacts the risk of developing pneumonia due to its regulation of immune cells and pro-inflammatory factors, 5,6 immunotherapy against lung cancer decrease COVID-19 severity and incidence of pneumonia to some extent. 7 Radiation may injure normal lung tissue and radiotherapy enhances the rate of pneumonia after SARS-CoV-2 infection. 8,9 At present, there is still a lack of safe and effective therapeutic drugs for COVID-19 in -Abstract Truncated-
immunology